Mexico's Genomma in market-maker program

19 January 2009

Mexico-based drugmaker Genomma Lab Internacional says it has signed an agreement with IXE Casa de Bolsa to act as the market-maker for the  company's outstanding shares, thus becoming another participant in the  program. The contract will become valid upon approval of the Mexican  Stock Exchange (Bolsa Mexicana de Valores) and will be in effect for a  minimum period of 12 months from the date of the agreement.

Less than six months since becoming a public company, Genomma Lab is  seeking to leverage the benefits of the modernizing Mexican markets via  the market-maker program. The company expects that its incorporation  into this program will allow for increased share liquidity.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight